Chronic kidney disease (CKD) is a public health crisis impacting 13.4% of the global population and is a leading cause of death in the United States. Counterintuitively, the amount of funding for and number of clinical research trials focusing on renal disease, does not reflect this relatively high prevalence. Instead, funding for CKD trials lags its incidence and is proportionally behind other diseases.
Frenova’s President, Kurt Mussina, describes the source of this disparity in funding and why it is crucial to address. From the need for new treatments to the ethics of patient suffering, CKD should be a much higher priority target for clinical research. In addition, its negative impact on the outcomes of other chronic conditions makes it important to a large variety of other disease fields, a fact which needs to be spread to clinical health professionals in those fields. Learn how you can be part of the solution by reading the article published in Clinical Researcher.
Author: Kurt Mussina, MBA
ACRP Clinical Researcher | November 16, 2021